Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Abstract Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15–60% of patients respond, leaving a broad swath of patients who do not derive benefit. Identifying biomarkers to optimally identify patients who will be...

Full description

Bibliographic Details
Main Authors: Satya Das, Douglas B. Johnson
Format: Article
Language:English
Published: BMJ Publishing Group 2019-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immune-related adverse events
Immune checkpoint inhibitor efficacy
Autoimmunity and anti-tumor effect
Anti-programmed cell death protein 1
Anti-programmed death-ligand 1
Anti-cytotoxic T-lymphocyte-associated protein 4
Online Access:http://link.springer.com/article/10.1186/s40425-019-0805-8

Internet

http://link.springer.com/article/10.1186/s40425-019-0805-8

Similar Items